These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 37880707)

  • 1. Antibody drug conjugates: hitting the mark in pancreatic cancer?
    Wittwer NL; Brown MP; Liapis V; Staudacher AH
    J Exp Clin Cancer Res; 2023 Oct; 42(1):280. PubMed ID: 37880707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer.
    Knutson S; Raja E; Bomgarden R; Nlend M; Chen A; Kalyanasundaram R; Desai S
    PLoS One; 2016; 11(6):e0157762. PubMed ID: 27336622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
    Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
    Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
    Jackson D; Stover D
    Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates come of age in oncology.
    Dumontet C; Reichert JM; Senter PD; Lambert JM; Beck A
    Nat Rev Drug Discov; 2023 Aug; 22(8):641-661. PubMed ID: 37308581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells.
    Nishii Y; Yamaguchi M; Kimura Y; Hasegawa T; Aburatani H; Uchida H; Hirata K; Sakuma Y
    Int J Oncol; 2015 Apr; 46(4):1781-7. PubMed ID: 25672256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
    Wolska-Washer A; Robak T
    Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Picking the optimal target for antibody-drug conjugates.
    Mathur R; Weiner GJ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively.
    Li WQ; Guo HF; Li LY; Zhang YF; Cui JW
    Cancer Med; 2021 Jul; 10(14):4677-4696. PubMed ID: 34165267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates: What drives their progress?
    Pander G; Uhl P; Kühl N; Haberkorn U; Anderl J; Mier W
    Drug Discov Today; 2022 Oct; 27(10):103311. PubMed ID: 35787480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
    Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis.
    Püsküllüoğlu M; Rudzińska A; Pacholczak-Madej R
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188991. PubMed ID: 37758021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.